Kornitzer Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$19.1M Sell
314,534
-590
-0.2% -$34.4K 0.41% 55
2025
Q4
$17M Buy
315,124
+9,015
+3% +$434K 0.35% 63
2025
Q3
$13.8M Sell
306,109
-1,518
-0.5% -$70.9K 0.28% 90
2025
Q2
$14.2M Sell
307,627
-2,734
-0.9% -$134K 0.29% 87
2025
Q1
$18.9M Buy
310,361
+3,844
+1% +$224K 0.39% 63
2024
Q4
$17.3M Buy
306,517
+15,130
+5% +$845K 0.34% 74
2024
Q3
$15.1M Buy
291,387
+1,040
+0.4% +$48.8K 0.28% 100
2024
Q2
$12.1M Buy
290,347
+8,768
+3% +$392K 0.23% 123
2024
Q1
$15.3M Buy
281,579
+13,436
+5% +$684K 0.28% 104
2023
Q4
$13.8M Buy
268,143
+3,884
+1% +$204K 0.27% 106
2023
Q3
$15.3M Sell
264,259
-315
-0.1% -$19.3K 0.32% 82
2023
Q2
$16.9M Buy
264,574
+8
+0% +$536 0.33% 82
2023
Q1
$18.3M Sell
264,566
-168
-0.1% -$11.8K 0.37% 75
2022
Q4
$19M Sell
264,734
-2,260
-0.8% -$170K 0.39% 70
2022
Q3
$19M Sell
266,994
-4,205
-2% -$305K 0.41% 65
2022
Q2
$20.9M Sell
271,199
-3,422
-1% -$261K 0.42% 67
2022
Q1
$20.1M Sell
274,621
-995
-0.4% -$66.8K 0.33% 97
2021
Q4
$17.2M Buy
275,616
+4,122
+2% +$242K 0.26% 147
2021
Q3
$16.1M Sell
271,494
-2,636
-1% -$174K 0.25% 160
2021
Q2
$18.3M Sell
274,130
-4,050
-1% -$264K 0.28% 144
2021
Q1
$17.6M Buy
278,180
+20,455
+8% +$1.27M 0.28% 131
2020
Q4
$16M Sell
257,725
-14,440
-5% -$888K 0.27% 131
2020
Q3
$16.4M Sell
272,165
-1,240
-0.5% -$74.6K 0.32% 108
2020
Q2
$16.1M Sell
273,405
-2,905
-1% -$174K 0.32% 108
2020
Q1
$15.4M Sell
276,310
-8,535
-3% -$522K 0.37% 97
2019
Q4
$18.3M Sell
284,845
-1,880
-0.7% -$108K 0.32% 110
2019
Q3
$14.5M Buy
286,725
+10,740
+4% +$505K 0.26% 122
2019
Q2
$12.5M Buy
275,985
+31,615
+13% +$1.47M 0.22% 143
2019
Q1
$11.7M Buy
244,370
+26,575
+12% +$1.32M 0.21% 147
2018
Q4
$11.3M Sell
217,795
-460
-0.2% -$24.7K 0.23% 137
2018
Q3
$13.5M Buy
218,255
+3,075
+1% +$182K 0.22% 145
2018
Q2
$11.9M Buy
215,180
+13,840
+7% +$747K 0.2% 147
2018
Q1
$12.7M Buy
201,340
+1,965
+1% +$126K 0.22% 141
2017
Q4
$12.2M Sell
199,375
-4,770
-2% -$298K 0.21% 148
2017
Q3
$13M Sell
204,145
-8,065
-4% -$471K 0.23% 140
2017
Q2
$11.8M Buy
212,210
+12,195
+6% +$664K 0.21% 158
2017
Q1
$10.9M Buy
200,015
+40,955
+26% +$2.25M 0.19% 163
2016
Q4
$9.29M Buy
159,060
+19,500
+14% +$1.07M 0.17% 186
2016
Q3
$7.53M Buy
139,560
+76,810
+122% +$4.93M 0.14% 213
2016
Q2
$4.62M Buy
62,750
+3,700
+6% +$261K 0.08% 251
2016
Q1
$3.77M Buy
59,050
+49,675
+530% +$3.13M 0.06% 265
2015
Q4
$645K Buy
9,375
+3,525
+60% +$233K 0.01% 388
2015
Q3
$346K Buy
5,850
+1,025
+21% +$65K 0.01% 407
2015
Q2
$321K Hold
4,825
﹤0.01% 419
2015
Q1
$311K Hold
4,825
﹤0.01% 413
2014
Q4
$285K Hold
4,825
﹤0.01% 398
2014
Q3
$247K Buy
4,825
+100
+2% +$5K ﹤0.01% 398
2014
Q2
$229K Buy
4,725
+25
+0.5% +$1.23K ﹤0.01% 403
2014
Q1
$244K Hold
4,700
﹤0.01% 403
2013
Q4
$250K Hold
4,700
﹤0.01% 399
2013
Q3
$218K Sell
4,700
-1,000
-18% -$43.9K ﹤0.01% 399
2013
Q2
$255K Buy
+5,700
New +$247K ﹤0.01% 386

Other funds holding BMY

Kornitzer Capital Management's BMY Position: Q1 2026 in Review

Kornitzer Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 0.19% in Q1 2026, selling an estimated $34.4K and leaving 314,534 shares worth $19.1M. The position accounts for 0.41% of the portfolio, ranked #55.

Kornitzer Capital Management first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $20.9M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Kornitzer Capital Management held 314,534 shares of Bristol-Myers Squibb worth $19.1M as of Q1 2026.
  • Kornitzer Capital Management sold 590 Bristol-Myers Squibb shares in Q1 2026, an estimated $34.4K.
  • Bristol-Myers Squibb made up 0.41% of Kornitzer Capital Management's portfolio in Q1 2026, its #55 holding.
  • Kornitzer Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Kornitzer Capital Management's Bristol-Myers Squibb position peaked at $20.9M in Q2 2022.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Kornitzer Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.